The clinical translation of a near-infrared fluorophore for fluorescence guided surgery: SGM-101 from the lab to a phase III trial

Ruben P. J. Meijer; Kim S. de Valk; Bérénice Framery; Marian Gutowski; André Pèlegrin; Françoise Cailler; Denise E. Hilling; Alexander L. Vahrmeijer

doi:10.1117/12.2555598

19 February 2020 The clinical translation of a near-infrared fluorophore for fluorescence guided surgery: SGM-101 from the lab to a phase III trial

Ruben P. J. Meijer, Kim S. de Valk, Bérénice Framery, Marian Gutowski, André Pèlegrin, Françoise Cailler, Denise E. Hilling, Alexander L. Vahrmeijer

Author Affiliations +

Proceedings Volume 11222, Molecular-Guided Surgery: Molecules, Devices, and Applications VI; 112220Q (2020) https://doi.org/10.1117/12.2555598
Event: SPIE BiOS, 2020, San Francisco, California, United States

Abstract

Near-infrared (NIR) fluorescence imaging is a promising intraoperative technique for real-time visualization of tumor tissue during surgery. The process of clinical translation of novel fluorescent agents is an essential part in the evolution of NIR fluorescence guided surgery. Poor visualization of tumors during surgery is one of the major challenges surgeons often face in oncologic patients, mainly due to the improved neo-adjuvant treatment patients receive. In these cases, NIR fluorescence imaging with the use of tumor-targeted fluorescent agents can play an essential role and help provide better oncologic results or patient outcomes. However, before this technique can be implemented in standard of care, optimal tumor-targeted fluorescent agents need to be developed and novel fluorescent agents need to undergo a successful process of clinical translation. Here we describe the clinical translation of SGM-101, a fluorescent anti-CEA monoclonal antibody.

Citation Download Citation

Ruben P. J. Meijer, Kim S. de Valk, Bérénice Framery, Marian Gutowski, André Pèlegrin, Françoise Cailler, Denise E. Hilling, and Alexander L. Vahrmeijer "The clinical translation of a near-infrared fluorophore for fluorescence guided surgery: SGM-101 from the lab to a phase III trial", Proc. SPIE 11222, Molecular-Guided Surgery: Molecules, Devices, and Applications VI, 112220Q (19 February 2020); https://doi.org/10.1117/12.2555598

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
6 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Surgery

Tumors

Luminescence

Colorectal cancer

Near infrared

Tissues

Cancer

Show All Keywords

Keywords/Phrases

Search In:

Publication Years